先聲藥業(02096.HK)新藥臨床試驗申請獲國家藥監局受理

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

先聲藥業(02096.HK)新藥臨床試驗申請獲國家藥監局受理

阿思達克 10-21 03:59

先聲藥業(02096.HK)就近期股價及成交量不尋常變動聲明，本月10日，公司自主研發的2項抗腫瘤候選藥物SIM0237及SIM0348新藥臨床試驗申請獲國家藥品監督管理局藥品審評中心受理。目前，尚未取得臨床試驗批准通知書。

先聲藥業(02096.HK)

Relevant Stocks

先聲藥業(02096.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

先聲藥業(02096.HK)新藥臨床試驗申請獲國家藥監局受理

Services

About Us

Agreement Statement